Recombinant Neisseria surface protein A is a potential vaccine candidate against Neisseria meningitides serogroup B

Ying,Shangyun; He,Jun; Yu,Minjun; Zhang,Yukuai; Deng,Suhong; Zhang,Lusi; Xie,Meihua; Hu,Sihai

doi:10.3892/mmr.2014.2325

Recombinant Neisseria surface protein A is a potential vaccine candidate against Neisseria meningitides serogroup B

Authors:
- Shangyun Ying
- Jun He
- Minjun Yu
- Yukuai Zhang
- Suhong Deng
- Lusi Zhang
- Meihua Xie
- Sihai Hu
View Affiliations

Affiliations: Pathogenic Biology Institute, College of Basic Medicine, University of South China, Hengyang, Hunan 421001, P.R. China
Published online on: June 13, 2014 https://doi.org/10.3892/mmr.2014.2325
Pages: 1619-1625

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Neisseria meningitidis is the pathogen of epidemic encephalomyelitis and is responsible for permanent damage to the brain and nervous system. In the present study, the prokaryotic expression vector pGEX-6p-1/neisseria surface protein A (NspA) was constructed and the immune protective effect was investigated with the purified recombinant rNspA. Female BALB/c mice were immunized by intraperitoneal inoculation of rNspA, glutathione S-transferase (GST) or phosphate-buffered saline (PBS). The protection experiment in mice demonstrated that the protection rate of the rNspA group was 85% against the N. meningitidis strain MC58, and a serum bactericidal assay in vitro revealed that the serum bactericidal titer of the rNspA group reached 1:64 following three immunizations. The levels of specific immunoglobulin (Ig) A (SIgA), IgG, IgG1, IgG2a, IgG2b and IgG3 of mice in the rNspA group peaked at week six and were higher than those in the mice in the GST and PBS groups. The levels of stimulation index, interleukin-4 and interferon-γ in the culture supernatant of the spleen lymphocytes of the rNspA group increased in a time-dependent manner and were higher than those of the mice in the GST and PBS groups over the same period. The results suggested that rNspA may induce increased specific humoral and cellular immune responses, and that it is effectively protective against N. meningitidis serogroup B in mice. The present study offered novel evidence that may lead to the development of a novel effective N. meningitidis serogroup B vaccine.

View Figures

View References

1	Braunstein M, Rajkumar P, Claus CL, Vaccarelli G, Moore AJ, Wang D and Anderson MK: HEBAlt enhances the T-cell potential of fetal myeloid-biased precursors. Int Immunol. 22:963–972. 2010. View Article : Google Scholar : PubMed/NCBI
2	van de Beek D, De Gans J, Spanjaard L, Weisfelt M, Reitsma JB and Vermeulen M: Clinical features and prognostic factors in adults with bacterial meningitis. N Engl J Med. 351:1849–1859. 2004.
3	Harrison LH, Mohan N and Kirkpatrick P: Meningococcal group A, C, Y and W-135 conjugate vaccine. Nat Rev Drug Discov. 9:429–430. 2010. View Article : Google Scholar : PubMed/NCBI
4	Khatami A and Pollard AJ: The epidemiology of meningococcal disease and the impact of vaccines. Expert Rev Vaccines. 9:285–298. 2010. View Article : Google Scholar : PubMed/NCBI
5	Águeda S, Campos T and Maia A: Prediction of bacterial meningitis based on cerebrospinal fluid pleocytosis in children. Braz J Infect Dis. 17:401–404. 2013.PubMed/NCBI
6	Raymond J: Neisseria meningitidis: characterisation and epidemiology. Arch Pediatr. 19(Suppl 2): S55–S60. 2012.(In French).
7	Ferguson LE, Hormann MD, Parks DK and Yetman RJ: Neisseria meningitidis: presentation, treatment, and prevention. J Pediatr Health Care. 16:119–124. 2002. View Article : Google Scholar : PubMed/NCBI
8	Findlow J, Lowe A, Deane S, Balmer P, van den Dobbelsteen G, Dawson M, Andrews N and Borrow R: Effect of sequence variation in meningococcal PorA outer membrane protein on the effectiveness of a hexavalent PorA outer membrane vesicle vaccine in toddlers and school children. Vaccine. 23:2623–2627. 2005. View Article : Google Scholar : PubMed/NCBI
9	van den Dobbelsteen GP, van Dijken HH, Pillai S and van Alphen L: Immunogenicity of a combination vaccine containing pneumococcal conjugates and meningococcal PorA OMVs. Vaccine. 25:2491–2496. 2007.PubMed/NCBI
10	Aaberge IS, Oster P, Helland OS, Kristoffersen AC, Ypma E, Høiby EA, Feiring B and Nøkleby H: Combined administration of meningococcal serogroup B outer membrane vesicle vaccine and conjugated serogroup C vaccine indicated for prevention of meningococcal disease is safe and immunogenic. Clin Diagn Lab Immunol. 12:599–605. 2005.
11	Zhou H, Gao Y, Xu L, Li M, Li Q, Li Y, Liang X, Luo H, Kan B, Xu J and Shao Z: Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008. Epidemiol Infect. 140:1296–1303. 2012.PubMed/NCBI
12	Yang L, Shao Z, Zhang X, Xu L, Peng J, Xu X, Liang X, Qi Y and Jin Q: Genotypic characterization of Neisseria meningitidis serogroup B strains circulating in China. J Infect. 56:211–218. 2008. View Article : Google Scholar : PubMed/NCBI
13	Panatto D, Amicizia D, Lai PL and Gasparini R: Neisseria meningitidis B vaccines. Expert Rev Vaccines. 10:1337–1351. 2011. View Article : Google Scholar
14	Silva GP, Cruz SC, Cruz AC and Milagres LG: Short-term and long-term antibody response by mice after immunization against Neisseria meningitidis B or diphtheria toxoid. Braz J Med Biol Res. 46:148–153. 2013. View Article : Google Scholar
15	Martin D, Cadieux N, Hamel J and Brodeur BR: Highly conserved Neisseria meningitidis surface protein confers protection against experimental infection. J Exp Med. 185:1173–1183. 1997. View Article : Google Scholar
16	Halperin SA, Langley JM, Smith B, Wunderli P, Kaufman L, Kimura A and Martin D: Phase 1 first-in-human studies of the reactogenicity and immunogenicity of a recombinant meningococcal NspA vaccine in healthy adults. Vaccine. 25:450–457. 2007. View Article : Google Scholar : PubMed/NCBI
17	Vandeputte-Rutten L, Bos MP, Tommassen J and Gros P: Crystal structure of Neisserial surface protein A (NspA), a conserved outer membrane protein with vaccine potential. J Biol Chem. 278:24825–24830. 2003. View Article : Google Scholar : PubMed/NCBI
18	Tsolakos N, Lie K, Bolstad K, Maslen S, Kristiansen PA, Hoiby EA, Wallington A, Vipond C, Skehel M, Tang CM, Feavers IM, Wedege E and Wheeler JX: Characterization of meningococcal serogroup B outer membrane vesicle vaccines from strain 44/76 after growth in different media. Vaccine. 28:3211–3218. 2010. View Article : Google Scholar
19	Zimmer SM and Stephens DS: Serogroup B meningococcal vaccines. Curr Opin Investig Drugs. 7:733–739. 2006.
20	Tamargo B, Márquez Y, Ramírez W, Cedré B, Fresno M and Sierra G: New proteoliposome vaccine formulation from N. meningitidis serogroup B, without aluminum hydroxide, retains its antimeningococcal protectogenic potential as well as Th-1 adjuvant capacity. BMC Immunol. 14(Suppl 1): S122013.PubMed/NCBI
21	Richmond P, Kaczmarski E, Borrow R, Findlow J, Clark S, McCann R, Hill J, Barker M and Miller E: Meningococcal C polysaccharide vaccine induces immunologic hyporesponsiveness in adults that is overcome by meningococcal C conjugate vaccine. J Infect Dis. 181:761–764. 2000. View Article : Google Scholar
22	Cassataro J, Velikovsky CA, Bruno L, Estein SM, de la Barrera S, Bowden R, Fossati CA and Giambartolomei GH: Improved immunogenicity of a vaccination regimen combining a DNA vaccine encoding Brucella melitensis outer membrane protein 31 (Omp31) and recombinant Omp31 boosting. Clin Vaccine Immunol. 14:869–874. 2007. View Article : Google Scholar : PubMed/NCBI
23	Martin D, Brodeur BR, Hamel J, Couture F, de Alwis U, Lian Z, Martin S, Andrews D and Ellis RW: Candidate Neisseria meningitidis NspA vaccine. J Biotechnol. 83:27–31. 2000. View Article : Google Scholar : PubMed/NCBI
24	Cadieux N, Plante M, Rioux CR, Hamel J, Brodeur BR and Martin D: Bactericidal and cross-protective activities of a monoclonal antibody directed against Neisseria meningitidis NspA outer membrane protein. Infect Immun. 67:4955–4959. 1999.PubMed/NCBI
25	Lewis LA, Ngampasutadol J, Wallace R, Reid JE, Vogel U and Ram S: The meningococcal vaccine candidate neisserial surface protein A (NspA) binds to factor H and enhances meningococcal resistance to complement. PLoS Pathog. 6:e10010272010. View Article : Google Scholar
26	Arenas J, Nijland R, Rodriguez FJ, Bosma TN and Tommassen J: Involvement of three meningococcal surface-exposed proteins, the heparin-binding protein NhbA, the α-peptide of IgA protease and the autotransporter protease NalP, in initiation of biofilm formation. Mol Microbiol. 87:254–268. 2013.PubMed/NCBI
27	Vaughan AT, Gorringe A, Davenport V, Williams NA and Heyderman RS: Absence of mucosal immunity in the human upper respiratory tract to the commensal bacteria Neisseria lactamica but not pathogenic Neisseria meningitidis during the peak age of nasopharyngeal carriage. J Immunol. 182:2231–2240. 2009. View Article : Google Scholar
28	Davenport V, Groves E, Horton RE, Hobbs CG, Guthrie T, Findlow J, Borrow R, Naess LM, Oster P, Heyderman RS and Williams NA: Mucosal immunity in healthy adults after parenteral vaccination with outer-membrane vesicles from Neisseria meningitidis serogroup B. J Infect Dis. 198:731–740. 2008. View Article : Google Scholar : PubMed/NCBI
29	Trotter CL, Yaro S, Njanpop-Lafourcade BM, Drabo A, Kroman SS, Idohou RS, Sanou O, Bowen L, Findlow H, Diagbouga S, Gessner BD, Borrow R and Mueller JE: Seroprevalence of bactericidal, specific IgG antibodies and incidence of meningitis due to group A Neisseria meningitidis by age in Burkina Faso 2008. PLoS One. 8:e554862013.PubMed/NCBI
30	Zhao F, Wang S, Zhang X, Gu W, Yu J, Liu S, Zeng T, Zhang Y and Wu Y: Protective efficacy of a Treponema pallidum Gpd DNA vaccine vectored by chitosan nanoparticles and fused with interleukin-2. Can J Microbiol. 58:117–123. 2012. View Article : Google Scholar
31	Haghi F, Peerayeh SN, Siadat SD and Montajabiniat M: Cloning, expression and purification of outer membrane protein PorA of Neisseria meningitidis serogroup B. J Infect Dev Ctries. 5:856–862. 2011.PubMed/NCBI
32	da Hora VP, Conceição FR, Dellagostin OA and Doolan DL: Non-toxic derivatives of LT as potent adjuvants. Vaccine. 29:1538–1544. 2011.PubMed/NCBI
33	Jung DJ, An JH, Kurokawa K, Jung YC, Kim MJ, Aoyagi Y, Matsushita M, Takahashi S, Lee HS, Takahashi K and Lee BL: Specific serum Ig recognizing staphylococcal wall teichoic acid induces complement-mediated opsonophagocytosis against Staphylococcus aureus. J Immunol. 189:4951–4959. 2012. View Article : Google Scholar
34	Kelly DF and Rappuoli R: Reverse vaccinology and vaccines for serogroup B Neisseria meningitidis. Adv Exp Med Biol. 568:217–223. 2005. View Article : Google Scholar : PubMed/NCBI